This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development

Newswire.ca - Fri Dec 19, 2025

DeFloria Advancing Charlotte's Web Legacy as Pioneer in Cannabinoid Health, with Phase 2 Clinical Trials for Autism Botanical Drug

LOUISVILLE, Colo. and WASHINGTON, Dec. 19, 2025 /CNW/ - DeFloria Inc., a botanical drug development Company recognizes the Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III, as a critical accelerator for cannabinoid medical innovation and regulatory reform. DeFloria is advancing a leading cannabinoid-based investigational new drug ("IND") through the FDA botanical drug pathway for autism-related irritability (AJA001 oral solution). The Executive Order represents pivotal federal acknowledgment of the therapeutic value of cannabinoids and validates a patient-centered movement that began more than a decade ago with the Stanley Brothers and their founding of Charlotte's Web (TSX: CWEB) (OTCQB: CWBHF).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).